About VIRxSYS
VIRxSYS was a Healthcare company based in Gaithersburg (United States) founded in 1998. It develops genetic therapies targeted at treating HIV and cancer. It operates on a B2B model. VIRxSYS has raised $105.92 million across 7 funding rounds. The company is recorded as dissolved. Its focus areas include Biotechnology, Genetic Therapies and HIV and Cancer Treatments. Its legal entity is VIRxSYS Corporation. Its competitors include Spark Therapeutics, Denali Therapeutics and AskBio; 3 of its 3 listed competitors have raised funding.
Company details
VIRxSYS develops genetic therapies targeted at treating hiv and cancer through providing healthcare solutions, advancing biotech innovations, genetic therapies, and hiv and cancer treatments. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Gaithersburg, United States
- SectorsHealthcare
- Website virxsys.com
- Legal Name Virxsys Corporation
- Total Equity Funding$105.92M (USD)
in 7 rounds
- Latest Funding Round$1000K (USD), Series H
Dec 2011
Funding Insights of VIRxSYS
VIRxSYS has successfully raised a total of $105.92M across 7 strategic funding rounds. The most recent funding activity was a Series H round of $1000 thousand completed in December 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $105.92M
- Total Rounds 7
- Last Round Series H — $999,999
- First Round $7.27M
(Sep 2002)
All 7 funding rounds of VIRxSYS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2011 | $999,999 | Series H | – | – | – |
| Apr 2011 | $33.81M | Series H | – | – | – |
| Dec 2006 | $20M | Series G | – | – | – |
| Oct 2005 | $31M | Series F | – | – | – |
| Jul 2004 | $10.02M | Series E | – | – | – |
| Jan 2004 | $2.82M | Series E | – | – | – |
| Sep 2002 | $7.27M | Series D | – | – | – |
Timeline of VIRxSYS
3 dated milestones of VIRxSYS across 13 years, from founding to its latest funding, stage changes and deals.
- Founded VIRxSYS is founded.
- Funding First funding round of $7.3M.
- Funding Latest funding round, Series H, of $1,000K.
Competitors of VIRxSYS
VIRxSYS has 3 listed competitors in our database, 3 of them funded. They include Spark Therapeutics, Denali Therapeutics and AskBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. |
Detailed competitors of VIRxSYS
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of VIRxSYS
Websites that share an audience with VIRxSYS (virxsys.com).
Websites whose visitors overlap most with VIRxSYS. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| superarray.com | 100% | View details | |||
| santaris.com | 99% | View details | |||
| takara-bio.com | 98% | 4K | #4,713,078 | View details | |
| sylentis.com | 87% | 3.9K | #4,931,838 | View details | |
| asuragen.com | 82% | 8.4K | #2,708,489 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for VIRxSYS
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as VIRxSYS (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about VIRxSYS
VIRxSYS was founded in 1998 and raised its 1st funding round 4 years after it was founded.
VIRxSYS is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
VIRxSYS is a funded company, having raised a total of $105.92M across 7 funding rounds to date. The company's 1st funding round was a Series D of $7.27M, raised on Sep 2002.
VIRxSYS develops genetic therapies targeted at treating hiv and cancer through providing healthcare solutions, advancing biotech innovations, genetic therapies, and hiv and cancer treatments. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
VIRxSYS's top competitors include Spark Therapeutics, AskBio and Denali Therapeutics.
VIRxSYS operates through Virxsys Corporation.